Literature DB >> 27753680

Non-neutralizing antibody functions for protection and control HIV in humans and SIV and SHIV in non-human primates.

Susan Zolla-Pazner1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27753680      PMCID： PMC5108572          DOI： 10.1097/QAD.0000000000001200

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  39 in total

1.  Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells.

Authors:  Vincent Holl; Maryse Peressin; Thomas Decoville; Sylvie Schmidt; Susan Zolla-Pazner; Anne-Marie Aubertin; Christiane Moog
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

2.  Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family.

Authors:  Mattia Bonsignori; Justin Pollara; M Anthony Moody; Michael D Alpert; Xi Chen; Kwan-Ki Hwang; Peter B Gilbert; Ying Huang; Thaddeus C Gurley; Daniel M Kozink; Dawn J Marshall; John F Whitesides; Chun-Yen Tsao; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Jerome H Kim; Nelson L Michael; Georgia D Tomaras; David C Montefiori; George K Lewis; Anthony DeVico; David T Evans; Guido Ferrari; Hua-Xin Liao; Barton F Haynes
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

3.  Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1.

Authors:  A Pinter; W J Honnen; S A Tilley; C Bona; H Zaghouani; M K Gorny; S Zolla-Pazner
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

Review 4.  Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines.

Authors:  Jean-Louis Excler; Julie Ake; Merlin L Robb; Jerome H Kim; Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2014-06-11

5.  Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.

Authors:  Johannes F Scheid; Hugo Mouquet; Niklas Feldhahn; Michael S Seaman; Klara Velinzon; John Pietzsch; Rene G Ott; Robert M Anthony; Henry Zebroski; Arlene Hurley; Adhuna Phogat; Bimal Chakrabarti; Yuxing Li; Mark Connors; Florencia Pereyra; Bruce D Walker; Hedda Wardemann; David Ho; Richard T Wyatt; John R Mascola; Jeffrey V Ravetch; Michel C Nussenzweig
Journal:  Nature       Date:  2009-03-15       Impact factor: 49.962

6.  Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2.

Authors:  Hua-Xin Liao; Mattia Bonsignori; S Munir Alam; Jason S McLellan; Georgia D Tomaras; M Anthony Moody; Daniel M Kozink; Kwan-Ki Hwang; Xi Chen; Chun-Yen Tsao; Pinghuang Liu; Xiaozhi Lu; Robert J Parks; David C Montefiori; Guido Ferrari; Justin Pollara; Mangala Rao; Kristina K Peachman; Sampa Santra; Norman L Letvin; Nicos Karasavvas; Zhi-Yong Yang; Kaifan Dai; Marie Pancera; Jason Gorman; Kevin Wiehe; Nathan I Nicely; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Jaranit Kaewkungwal; Punnee Pitisuttithum; James Tartaglia; Faruk Sinangil; Jerome H Kim; Nelson L Michael; Thomas B Kepler; Peter D Kwong; John R Mascola; Gary J Nabel; Abraham Pinter; Susan Zolla-Pazner; Barton F Haynes
Journal:  Immunity       Date:  2013-01-11       Impact factor: 31.745

7.  Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function.

Authors:  Amy W Chung; Max Crispin; Laura Pritchard; Hannah Robinson; Miroslaw K Gorny; Xiaojie Yu; Chris Bailey-Kellogg; Margaret E Ackerman; Chris Scanlan; Susan Zolla-Pazner; Galit Alter
Journal:  AIDS       Date:  2014-11-13       Impact factor: 4.177

8.  Reproducing SIVΔnef vaccine correlates of protection: trimeric gp41 antibody concentrated at mucosal front lines.

Authors:  James E Voss; Matthew S Macauley; Kenneth A Rogers; Francois Villinger; Lijie Duan; Liang Shang; Elizabeth A Fink; Raiees Andrabi; Arnaud D Colantonio; James E Robinson; R Paul Johnson; Dennis R Burton; Ashley T Haase
Journal:  AIDS       Date:  2016-10-23       Impact factor: 4.177

9.  Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines.

Authors:  Amy W Chung; Musie Ghebremichael; Hannah Robinson; Eric Brown; Ickwon Choi; Sophie Lane; Anne-Sophie Dugast; Matthew K Schoen; Morgane Rolland; Todd J Suscovich; Alison E Mahan; Larry Liao; Hendrik Streeck; Charla Andrews; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Mark S de Souza; Jaranit Kaewkungwal; Punnee Pitisuttithum; Donald Francis; Nelson L Michael; Jerome H Kim; Chris Bailey-Kellogg; Margaret E Ackerman; Galit Alter
Journal:  Sci Transl Med       Date:  2014-03-19       Impact factor: 17.956

10.  Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.

Authors:  David C Montefiori; Chitraporn Karnasuta; Ying Huang; Hasan Ahmed; Peter Gilbert; Mark S de Souza; Robert McLinden; Sodsai Tovanabutra; Agnes Laurence-Chenine; Eric Sanders-Buell; M Anthony Moody; Mattia Bonsignori; Christina Ochsenbauer; John Kappes; Haili Tang; Kelli Greene; Hongmei Gao; Celia C LaBranche; Charla Andrews; Victoria R Polonis; Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Steve G Self; Phillip W Berman; Donald Francis; Faruk Sinangil; Carter Lee; Jim Tartaglia; Merlin L Robb; Barton F Haynes; Nelson L Michael; Jerome H Kim
Journal:  J Infect Dis       Date:  2012-05-25       Impact factor: 5.226
View more
  4 in total

1.  A Recombinant Rabies Virus Expressing the Marburg Virus Glycoprotein Is Dependent upon Antibody-Mediated Cellular Cytotoxicity for Protection against Marburg Virus Disease in a Murine Model.

Authors:  Rohan Keshwara; Katie R Hagen; Tiago Abreu-Mota; Amy B Papaneri; David Liu; Christoph Wirblich; Reed F Johnson; Matthias J Schnell
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

2.  Effect of polymorphisms in porcine guanylate-binding proteins on host resistance to PRRSV infection in experimentally challenged pigs.

Authors:  Amina Khatun; Salik Nazki; Chang-Gi Jeong; Suna Gu; Sameer Ul Salam Mattoo; Sim-In Lee; Myun-Sik Yang; Byeonghwi Lim; Kwan-Suk Kim; Bumseok Kim; Kyoung-Tae Lee; Choi-Kyu Park; Sang-Myeong Lee; Won-Il Kim
Journal:  Vet Res       Date:  2020-02-19       Impact factor: 3.683

Review 3.  Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond Neutralization.

Authors:  Bin Su; Stefania Dispinseri; Valeria Iannone; Tong Zhang; Hao Wu; Raphael Carapito; Seiamak Bahram; Gabriella Scarlatti; Christiane Moog
Journal:  Front Immunol       Date:  2019-12-18       Impact factor: 7.561

4.  Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies.

Authors:  Victoria Roulstone; David Mansfield; Robert J Harris; Katie Twigger; Christine White; Johann de Bono; James Spicer; Sophia N Karagiannis; Richard Vile; Hardev Pandha; Alan Melcher; Kevin Harrington
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.